The Food and Drug Administration (FDA) yesterday approved Adimmune Corp’s (國光生技) application to conduct phase I clinical trials of its COVID-19 candidate vaccine, making it the first in the nation to get the green light, the company said in a filing with the Taiwan Stock Exchange yesterday.
The FDA on Monday granted Adimmune conditional approval for its clinical trial application, asking it to submit additional technical data.
After complying with the request, the company received full approval yesterday, it said in a press release.
Adimmune plans to start human tests by the end of this month, after finalizing details with its trial partner, National Taiwan University Hospital (NTUH), in a few days, spokesperson Pan Fei (潘飛) told the Taipei Times by telephone.
The company’s “AdimrSC-2f vaccine” is designed to cause the body to produce antibodies against the novel coronavirus’ spike protein, which the virus uses to bind to and enter human cells.
Adimmune plans to enroll 60 to 70 healthy adult participants, who would be divided into three groups that would receive low, medium and high doses of the drug, Pan said.
Like its peer Moderna Inc, whose mRNA vaccine has entered into phase III trials, Adimmune would monitor participants to see if they show severe side effects after injection and would accordingly select two dose levels that are safer to continue testing in the later phase of testing, he said.
Adimmune would monitor the patients for four months, with plans to conduct an interim analysis in late October or early November, he added.
The trial would be conducted by NTUH’s Infectious Disease Division professor Chang Shan-chwen (張上淳), who is also the Central Epidemic Command Center’s (CECC) specialist advisory panel convener, as the government is highly concerned about the trial’s results, he said.
To speed up development of the vaccine, Adimmune intends to combine the phase II and phase III trials into a phase II/III design and run the final phase in November, subject to FDA approval, he said.
In related news, EirGenix Inc (台康生技), Panion & BF Biotech Inc (寶齡富錦) and AnTaimmu BioMed Co (安?生醫) yesterday applied to the FDA for approval of their rapid antigen tests for COVID-19, they said in stock exchange filings.
The three companies’ new test kits use antibodies to detect viruses and they can deliver results in a few minutes, compared with other types of test kits that require screening equipment and take hours to deliver results, they said.
After several years flying high as Asia’s best Nvidia Corp proxy, Taiwan Semiconductor Manufacturing Co (TSMC, 台積電) is increasingly vying with other artificial intelligence (AI) stocks for investor attention. Stock traders are chasing a wider array of beneficiaries as mainstream usage of AI creates demand for hardware beyond the most-advanced chips TSMC makes for Nvidia. Subthemes from the deepening memory crunch to advances in robotics are also luring bids. At the same time, investment caps on single stocks are pushing funds to diversify, while retail investors long familiar with TSMC through its US depositary receipts are being offered a broader set of
UNDER MICROSCOPE: Taiwan detained three people who allegedly conspired to buy servers in Taiwan and export them using fraudulent documentation, prosecutors said Nvidia Corp chief executive officer Jensen Huang (黃仁勳) on Saturday urged Super Micro Computer Inc to tighten up on compliance after Taiwan detained three people this week for allegedly making fraudulent declarations about artificial intelligence (AI) servers made by its US partner. The development marked the nation’s first crackdown on semiconductor smuggling, which grew after the US slapped restrictions on exports of high-end chips such as Nvidia AI accelerators to China. Nvidia is “rigorous” in explaining regulations to all of its partners, Huang told reporters after arriving in Taipei. “Ultimately Super Micro has to run their own company,” he said in response to
TECH RELIANCE: Growth is increasingly reflecting an unequal K-shaped distribution, where technology sectors outperform and other industries struggle, an expert said Standard Chartered Bank has significantly raised its forecast for Taiwan’s economic growth to 9.5 percent this year, up from 7.6 percent previously, citing surging artificial intelligence (AI) demand driving exports, semiconductor production and investment. The upgrade reflects a sustained AI supercycle that continues to fuel demand for advanced chips and technology infrastructure, which form the backbone of Taiwan’s exports, the bank said in a report this week. “We raise our 2026 growth forecast to reflect a much stronger-than-expected first-quarter GDP figure,” Standard Chartered senior economist for greater China and Asia Tommy Wu (胡東安) said in the report. Driven largely by a 35.3 percent
Two of Taiwan’s international carriers, Starlux Airlines Co (星宇航空) and EVA Airways Corp (長榮航空), have retained the five-star airline rating awarded by international airline review organization Skytrax. Starlux was awarded the distinction for a second consecutive year, while EVA Air received it for the 11th straight year, Skytrax said in statements released yesterday and on Thursday last week, respectively. The five-star rating is considered one of the airline industry's highest honors and is awarded following professional audits of airline product and frontline service standards, Skytrax said. The ratings are based on in-depth assessments using unified global quality standards rather than customer review scores
RSS